الفهرس 
acknowledgement
IncidenceOnly 14 pages are availabe for public view
 |  | from | 65 |  |  |
| | | from | 65 | | |
Abstract
This is a retrospective study included 47 cases with stage II- III breast cancer, pathologically diagnosed with infilterating ductal carcinoma, underwent surgery and received anthracyclin based adjuvant chemotherapy, they received adjuvant hypofractionated radiation therapy 4240 cGy in 16 fractions, 5 fractions per week with boost 14 Gy over 7 fractions after BCS to the lumpectomy bed, concurrently with capecitabine 825 mg /m2 every 12 hour on radiotherapy days. We followed up the patient for a period of 60 months to evaluate the late toxicities and the treatment outcome, 7 cases were lost during the follow up period.
Regarding the radiation therapy toxicity, there was no grade III or IV toxicities reported in our study group, most of patients had GI-II toxicity and improvent occurred along the follow up period.
Regarding the treatment outcomes Adjuvant hypofractionated radiation therapy combined with capeciabine is effective in reduction of disease recurrence and improving DFS .The 5 years DFS in patients with tumor stage II was 100% and in tumor stage III was 62.5 %.
Conclusion: concurrent capecitabine with adjuvant RT is well tolerated, safe and effective in the term of locoregional control and improving DFS.
Recommendation: large prospective studies and longer follow up is needed.